Mycenax Biotech (TWO: 4726) held its investor conference on May 31, 2024. In the field of traditional biologics, two Phase III projects are currently undergoing pre-market review, and two emerging drug development services have started contributing to revenue. Mycenax Biotech is (1) the only CDMO in Taiwan fully dedicated to providing CDMO services, (2) the service provider with the most comprehensive supply chain (from DNA to DP), (3) the only one focusing equally on traditional biologics and emerging biologics (BsAb, ADC, cell therapy), and (4) the CDMO company with the highest percentage of foreign investment.
Mycenax Biotech (TWO: 4726) held its investor conference on May 31, 2024. In the field of traditional biologics, two Phase III projects are currently undergoing pre-market review, and two emerging drug development services have started contributing to revenue. Mycenax Biotech is (1) the only CDMO in Taiwan fully dedicated to providing CDMO services, (2) the service provider with the most comprehensive supply chain (from DNA to DP), (3) the only one focusing equally on traditional biologics and emerging biologics (BsAb, ADC, cell therapy), and (4) the CDMO company with the highest percentage of foreign investment.